Subunit vaccines of the future: The need for safe, customized and optimized particulate delivery systems

Therapeutic Delivery

Volumn 2, Issue 8, 2011, Pages 1057-1077

  Foged, Camilla ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUPHOS; ALUMINUM HYDROXIDE; ALUMINUM PHOSPHATE; ALUMINUM POTASSIUM SULFATE; AS 01; AS 02; AS 03; AS 04; CAF 01; CANCER VACCINE; CHITOSAN DERIVATIVE; CIMAVAX EGF; CPG OLIGODEOXYNUCLEOTIDE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; ISCOM; LIPOSOME; MALARIA VACCINE; MIFAMURTIDE; MONTANIDE ISA 51; NY ESO 1 ANTIGEN; PHOSPHORYL LIPID A; POLYINOSINIC POLYCYTIDYLIC ACID; TETANUS TOXOID; TREHALOSEDIBEHENATE; UNCLASSIFIED DRUG; VACCINE; WART VIRUS VACCINE;

ADJUVANT THERAPY; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; BIOCOMPATIBILITY; BIODEGRADABILITY; CANCER PREVENTION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED DRUG RELEASE; CROSS PRESENTATION; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SAFETY; DRUG WITHDRAWAL; EMULSION; HEPATITIS A; HUMAN; HYDROPHOBICITY; IMMUNOGENICITY; IMMUNOPOTENTIATION; IMMUNOSTIMULATION; INJECTION SITE REACTION; LUNG NON SMALL CELL CANCER; NEOPLASM; NONHUMAN; PANDEMIC INFLUENZA; PARTICLE SIZE; PRIORITY JOURNAL; REVIEW; SEROCONVERSION; SURFACE CHARGE; UNSPECIFIED SIDE EFFECT; VIRUS LIKE AGENT;

EID: 80052422744     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.11.68     Document Type: Review

References (208)

1. Bloom DE, Canning D, Weston M. The value of vaccination. World Economics 6(3), 15-39 (2005).
2. Ehreth J. The value of vaccination: a global perspective. Vaccine 21(27-30), 4105-4117 (2003). (Pubitemid 37130255)
3. Rappuoli R, Miller HI, Falkow S. Medicine-the intangible value of vaccination. Science 297(5583), 937-940 (2002).
4. Rappuoli R. Bridging the knowledge gaps in vaccine design. Nat. Biotechnol. 25(12), 1361-1366 (2007). (Pubitemid 350233122)
5. Mbow ML, De Gregorio E, Valiante NM, Rappuoli R. New adjuvants for human vaccines. Curr. Opin. Immunol. 22(3), 411-416 (2010).
6. Reed SG, Bertholet S, Coler RN, Friede M. New horizons in adjuvants for vaccine development. Trends Immunol. 30(1), 23-32 (2009).
7. O'Hagan DT, De Gregorio E. The path to a successful vaccine adjuvant-the long and winding road. Drug Discov. Today 14(11-12), 541-551 (2009).
8. O'Hagan DT, Valiante NM. Recent advances in the discovery and delivery of vaccine adjuvants. Nat. Rev. Drug Discovery 2(9), 727-735 (2003). (Pubitemid 37361788)
9. Guy B. The perfect mix: recent progress in adjuvant research. Nat. Rev. Microbiol. 5(7), 505-517 (2007). (Pubitemid 46925379)
10. Dagan R, Poolman J, Siegrist CA. Glycoconjugate vaccines and immune interference: a review. Vaccine 28(34), 5513-5523 (2010).
11. Clements CJ, Griffths E. The global impact of vaccines containing aluminium adjuvants. Vaccine 20, S24-S33 (2002). (Pubitemid 34607672)
12. Lindblad EB. Aluminium adjuvants-in retrospect and prospect. Vaccine 22(27-28), 3658-3668 (2004).
13. Hem SL, Hogenesch H. Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation. Expert Rev. Vaccines 6(5), 685-698 (2007). (Pubitemid 47607846)
14. Clapp T, Siebert P, Chen D, Jones BL. Vaccines with aluminum-containing adjuvants: optimizing vaccine effcacy and thermal stability. J. Pharm. Sci. 100(2), 388-401 (2011).
15. Marrack P, Mckee AS, Munks MW. Towards an understanding of the adjuvant action of aluminium. Nat. Rev. Immunol. 9(4), 287-293 (2009).
16. Glenny AT, Pope CG, Waddington H, Wallace U. Immunological notes XVLL-XXIV J. Pathol. Bacteriol. 29(1), 31-40 (1926).
17. Morefeld GL, Sokolovska A, Jiang DP, Hogenesch H, Robinson JP, Hem SL. Role of aluminum-containing adjuvants in antigen internalization by dendritic cells in vitro. Vaccine 23(13), 1588-1595 (2005). (Pubitemid 40203396)
18. Tritto E, Mosca F, De Gregorio E. Mechanism of action of licensed vaccine adjuvants. Vaccine 27(25-26), 3331-3334 (2009).
19. Goto N, Kato H, Maeyama J et al. Local tissue irritating effects and adjuvant activities of calcium phosphate and aluminium hydroxide with different physical properties. Vaccine 15(12-13), 1364-1371 (1997). (Pubitemid 27397815)
20. Flach TL, Ng G, Hari A et al. Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity. Nat. Med. 17(4), 479-487 (2011).
21. Nordly P, Madsen HB, Nielsen HM, Foged C. Status and future prospects of lipid-based particulate delivery systems as vaccine adjuvants and their combination with immunostimulators. Expert Opin. Drug Deliv. 6(7), 657-672 (2009).
22. O'Hagan DT, Rappuoli R, De GE, Tsai T, Del GG. MF59 adjuvant: the best insurance against infuenza strain diversity. Expert Rev. Vaccines 10(4), 447-462 (2011).
23. Schultze V, DAgosto V, Wack A, Novicki D, Zorn J, Hennig R. Safety of MF59 (TM) adjuvant. Vaccine 26(26), 3209-3222 (2008).
24. Ott G, Barchfeld GL, Chernoff D, Radhakrishnan R, van Hoogevest P, Van Nest G. MF59. Design and evaluation of a safe and potent adjuvant for human vaccines. Pharm. Biotechnol. 6, 277-296 (1995).
25. Banzhoff A, Gasparini R, Laghi-Pasini F et al. MF59 (R)-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PloS One 4(2), e4384 (2009).
26. ®) in adult and elderly subjects. Int. J. Clin. Pract. 64(4), 432-438 (2010).
27. Galli G, Hancock K, Hoschler K et al. Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine. Proc. Natl Acad. Sci. USA 106(19), 7962-7967 (2009).
28. + T cell response that predicts long-term persistence of protective antibody levels. Proc. Natl Acad. Sci. USA 106(10), 3877-3882 (2009).
29. Garcon N, Chomez P, Van Mechelen M. GlaxoSmithKline Adjuvant systems in vaccines: concepts, achievements and perspectives. Expert Rev. Vaccines 6(5), 723-739 (2007). (Pubitemid 47607848)
30. Roman F, Vaman T, Gerlach B, Markendorf A, Gillard P, Devaster JM. Immunogenicity and safety in adults of one dose of infuenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial. Vaccine 28(7), 1740-1745 (2010).
31. Walker WT, Faust SN. Monovalent inactivated split-virion AS03-adjuvanted pandemic infuenza A (H1N1) vaccine. Expert Rev. Vaccines 9(12), 1385-1398 (2010).
32. Clark T W, Pareek M, Hoschler K et al. Trial of 2009 infuenza A (H1N1) monovalent MF59-adjuvanted vaccine. N. Engl. J. Med. 361(25), 2424-2435 (2009).
33. Caillet C, Durrieu G, Jacquet A et al. Safety surveillance of infuenza A(H1N1)v monovalent vaccines during the 2009-2010 mass vaccination campaign in France. Eur. J. Clin. Pharmacol. (2010).
34. Caillet C, Piras F, Bernard MC et al. AF03-adjuvanted and non-adjuvanted pandemic infuenza A (H1N1) 2009 vaccines induce strong antibody responses in seasonal infuenza vaccine-primed and unprimed mice. Vaccine 28(18), 3076-3079 (2010).
35. Mosca F, Tritto E, Muzzi A et al. Molecular and cellular signatures of human vaccine adjuvants. Proc. Natl Acad. Sci. USA 105(30), 10501-10506 (2008).
36. Fox CB, Anderson RC, Dutill TS, Goto Y, Reed SG, Vedvick TS. Monitoring the effects of component structure and source on formulation stability and adjuvant activity of oil-in-water emulsions. Colloids Surf. B 65(1), 98-105 (2008).
37. Calabro S, Tortoli M, Baudner BC et al. Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. Vaccine 29(9), 1812-1823 (2011).
38. Dupuis M, Murphy TJ, Higgins D et al. Dendritic cells internalize vaccine adjuvant after intramuscular injection. Cell Immunol. 186(1), 18-27 (1998). (Pubitemid 28285344)
39. Ellebedy AH, Lupfer C, Ghoneim HE, DeBeauchamp J, Kanneganti TD, Webby RJ. Infammasome-independent role of the apoptosis-associated speck-like protein containing CARD (ASC) in the adjuvant effect of MF59. Proc. Natl Acad. Sci. USA 108(7), 2927-2932 (2011).
40. + T cells in melanoma patients. J. Immunother. 31(8), 781-791 (2008).
41. Kakimi K, Isobe M, Uenaka A et al. A Phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen. Int. J. Cancer DOI: 10.1002/ijc.25955 (2011) (Epub ahead of print).
42. Diefenbach CSM, Gnjatic S, Sabbatini P et al. Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk frst remission. Clin. Cancer Res. 14(9), 2740-2748 (2008).
43. Rodriguez PC, Rodriguez G, Gonzalez G, Lage A. Clinical development and perspectives of CIMAvax EGF, cuban vaccine for non-small-cell lung cancer therapy. MEDICC Rev. 12(1), 17-23 (2010).
44. Graham BS, McElrath MJ, Keefer MC et al. Immunization with cocktail of HIV-derived peptides in montanide ISA-51 is immunogenic, but causes sterile abscesses and unacceptable reactogenicity. PloS One 5(8), e11995 (2010).
45. Wu Y, Ellis RD, Shaffer D et al. Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. PloS One 3(7), e2636 (2008).
46. Schiller JT, Castellsague X, Villa LL, Hildesheim A. An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine 26(Suppl. 10), K53-K61 (2008).
47. Gluck R, Metcalfe IC. New technology platforms in the development of vaccines for the future. Vaccine 20(Suppl. 5), B10-B16 (2002). (Pubitemid 35435391)
48. Christensen D, Korsholm KS, Rosenkrands I, Lindenstrom T, Andersen P, Agger EM. Cationic liposomes as vaccine adjuvants. Expert Rev. Vaccines 6(5), 785-796 (2007). (Pubitemid 47607853)
49. ®) in elderly subjects. Vaccine 24(44-46), 6629-6631 (2006). (Pubitemid 46107151)
50. Bovier PA. Recent advances with a virosomal hepatitis A vaccine. Expert Opin. Biol. Therapy 8(8), 1177-1185 (2008).
51. Campo MS, Roden RB. Papillomavirus prophylactic vaccines: established successes, new approaches. J. Virol. 84(3), 1214-1220 (2010).
52. 2+ following B-cell receptor activation. EMBO J. 17(7), 1973-1985 (1998). (Pubitemid 28154527)
53. Deml L, Speth C, Dierich MP, Wolf H, Wagner R. Recombinant HIV-1 Pr55gag virus-like particles: potent stimulators of innate and acquired immune responses. Mol. Immunol. 42(2), 259-277 (2005). (Pubitemid 39361454)
54. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discovery 4(2), 145-160 (2005). (Pubitemid 40282557)
55. Frazer IH, Quinn M, Nicklin JL et al. Phase 1 study of HPV16-specifc immunotherapy with E6E7 fusion protein and Iscomatrix™ adjuvant in women with cervical intraepithelial neoplasia. Vaccine 23(2), 172-181 (2004). (Pubitemid 39505086)
56. ® and Iscomatrix™. Vaccine 27(33), 4388-4401 (2009).
57. Nakanishi T, Hayashi A, Kunisawa J et al. Fusogenic liposomes effciently deliver exogenous antigen through the cytoplasm into the MHC class I processing pathway. Eur. J. Immunol. 30(6), 1740-1747 (2000). (Pubitemid 30342818)
58. De Koker S, Lambrecht BN, Willart MA et al. Designing polymeric particles for antigen delivery. Chem. Soc. Rev 40(1), 320-339 (2011).
59. Langer R, Cleland JL, Hanes J. New advances in microsphere-based single-dose vaccines. Adv. Drug Delivery Rev. 28(1), 97-119 (1997). (Pubitemid 27497676)
60. Johansen P, Gomez JMM, Gander B. Development of synthetic biodegradable microparticulate vaccines: a roller coaster story. Expert Rev. Vaccines 6(4), 471-474 (2007). (Pubitemid 47304024)
61. Tamber H, Johansen P, Merkle HP, Gander B. Formulation aspects of biodegradable polymeric microspheres for antigen delivery. Adv. Drug Delivery Rev. 57(3), 357-376 (2005). (Pubitemid 39555502)
62. Putney SD, Burke PA. Improving protein therapeutics with sustained-release formulations. Nat. Biotechnol. 16(2), 153-157 (1998). (Pubitemid 128723585)
63. Johansen P, Estevez F, Zurbriggen R et al. Towards clinical testing of a single-administration tetanus vaccine based on PLA/PLGA microspheres. Vaccine 19(9-10), 1047-1054 (2000). (Pubitemid 32008269)
64. Feng L, Qi MR, Zhou XJ et al. Pharmaceutical and immunological evaluation of a single-dose hepatitis B vaccine using PLGA microspheres. J. Control. Release 112(1), 35-42 (2006).
65. Fischer S, Schlosser E, Mueller M et al. Concomitant delivery of a CTL-restricted peptide antigen and CpG ODN by PLGA microparticles induces cellular immune response. J. Drug Targeting 17(8), 652-661 (2009).
66. Kasturi SP, Skountzou I, Albrecht RA et al. Programming the magnitude and persistence of antibody responses with innate immunity. Nature 470(7335), 543-547 (2011).
67. Arca HC, Gunbeyaz M, Senel S. Chitosan-based systems for the delivery of vaccine antigens. Expert Rev. Vaccines 8(7), 937-953 (2009).
68. Amidi M, Mastrobattista E, Jiskoot W, Hennink WE. Chitosan-based delivery systems for protein therapeutics and antigens. Adv. Drug Delivery Rev. 62(1), 59-82 (2010).
69. El-Kamary SS, Pasetti MF, Mendelman PM et al. Adjuvanted intranasal norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues. J. Infect. Dis. 202(11), 1649-1658 (2010).
70. Baudner BC, Verhoef JC, Giuliani MM et al. Protective immune responses to meningococcal C conjugate vaccine after intranasal immunization of mice with the LTK63 mutant plus chitosan or trimethyl chitosan chloride as novel delivery platform. J. Drug Targeting 13(8-9), 489-498 (2005). (Pubitemid 43347846)
71. Hagenaars N, Verheul RJ, Mooren I et al. Relationship between structure and adjuvanticity of N,N,N-trimethyl chitosan (TMC) structural variants in a nasal infuenza vaccine. J. Control. Release 140(2), 126-133 (2009).
72. Hagenaars N, Mania M, de Jong P et al. Role of trimethylated chitosan (TMC) in nasal residence time, local distribution and toxicity of an intranasal infuenza vaccine. J. Control. Release 144(1), 17-24 (2010).
73. Porporatto C, Bianco ID, Correa SG. Local and systemic activity of the polysaccharide chitosan at lymphoid tissues after oral administration. J. Leukocyte Biol. 78(1), 62-69 (2005). (Pubitemid 40979944)
74. Nagamoto T, Hattori Y, Takayama K, Maitani Y. Novel chitosan particles and chitosan-coated emulsions inducing immune response via intranasal vaccine delivery. Pharm. Res. 21(4), 671-674 (2004). (Pubitemid 38457290)
75. Slutter B, Bal SM, Que I et al. Antigen-adjuvant nanoconjugates for nasal vaccination: an improvement over the use of nanoparticles? Mol. Pharmaceutics 7(6), 2207-2215 (2010).
76. De Koker S, De Geest BG, Singh SK et al. Polyelectrolyte microcapsules as antigen delivery vehicles to dendritic cells: uptake, processing, and cross-presentation of encapsulated antigens. Angew. Chem., Int. Ed. 48(45), 8485-8489 (2009).
77. De Haes W, De Koker S, Pollard C et al. Polyelectrolyte capsules-containing HIV-1 p24 and poly I:C modulate dendritic cells to stimulate HIV-1-specifc immune responses. Mol. Ther. 18(7), 1408-1416 (2010).
78. Iwasaki A, Medzhitov R. Regulation of adaptive immunity by the innate immune system. Science 327(5963), 291-295 (2010).
79. Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. Immunity 33(4), 492-503 (2010).
80. Janeway CA Jr. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb. Symp. Quant. Biol. 54 Pt 1, 1-13 (1989). (Pubitemid 20177564)
81. Vivier E, Malissen B. Innate and adaptive immunity: specifcities and signaling hierarchies revisited. Nat. Rev. Immunol. 6(1), 17-21 (2005). (Pubitemid 40136691)
82. Medzhitov R, Janeway CA Jr. Decoding the patterns of self and nonself by the innate immune system. Science 296(5566), 298-300 (2002). (Pubitemid 34303673)
83. Duthie MS, Windish HP, Fox CB, Reed SG. Use of defned TLR ligands as adjuvants within human vaccines. Immunol. Rev. 239(1), 178-196 (2011).
84. Medzhitov R, Preston-Hurlburt P, Janeway CA. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388(6640), 394-397 (1997). (Pubitemid 27334820)
85. Akira S, Takeda K. Toll-like receptor signalling. Nat. Rev. Immunol. 4(7), 499-511 (2004). (Pubitemid 38931765)
86. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 11(5), 373-384 (2010).
87. Takeda K, Akira S. Toll-like receptors in innate immunity. Int. Immunol. 17(1), 1-14 (2005).
88. Medzhitov R. Toll-like receptors and innate immunity. Nat. Rev. Immunol. 1(2), 135-145 (2001). (Pubitemid 33741967)
89. Gay NJ, Gangloff M. Structure and function of Toll receptors and their ligands. Annu. Rev. Biochem. 76, 141-165 (2007).
90. Philpott DJ, Girardin SE. The role of Toll-like receptors and Nod proteins in bacterial infection. Mol. Immunol. 41(11), 1099-1108 (2004). (Pubitemid 39345391)
91. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 20, 709-760 (2002). (Pubitemid 34293438)
92. Agrawal S, Agrawal A, Doughty B et al. Cutting edge: different Toll-like receptor agonists instruct dendritic cells to induce distinct Th responses via differential modulation of extracellular signal-regulated kinase-mitogen- activated protein kinase and c-Fos. J. Immunol. 171(10), 4984-4989 (2003). (Pubitemid 37432777)
93. Zaks K, Jordan M, Guth A et al. Effcient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes. J. Immunol. 176(12), 7335-7345 (2006). (Pubitemid 43849034)
94. Durand V, Wong SY, Tough DF, Le BA. Shaping of adaptive immune responses to soluble proteins by TLR agonists: a role for IFN-a/b. Immunol. Cell Biol. 82(6), 596-602 (2004). (Pubitemid 39563960)
95. Le Bon A, Tough DF. Type I interferon as a stimulus for cross-priming. Cytokine Growth Factor Rev. 19(1), 33-40 (2008).
96. + T cells to intracellular bacteria. Curr. Opin. Immunol. 11(1), 89-93 (1999). (Pubitemid 29082343)
97. Casella CR, Mitchell TC. Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant. Cell. Mol. Life Sci. 65(20), 3231-3240 (2008).
98. Garcon N. Preclinical development of AS04. Methods Mol. Biol. 626, 15-27 (2010).
99. Schwarz T. Clinical update of the AS04-Adjuvanted human Papillomavirus-16/18 cervical cancer vaccine, cervarix. Adv. Ther. 26(11), 983-998 (2009).
100. The GlaxoSmithKline Vaccine HPV-007 Study Group: Sustained effcacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: ana lysis of a randomised placebo-controlled trial up to 6+4 years. The Lancet 374(9706), 1975-1985 (2009).
101. Giannini SL, Hanon E, Moris P et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared with aluminium salt only. Vaccine 24(33-34), 5937-5949 (2006). (Pubitemid 44080367)
102. Didierlaurent AM, Morel S, Lockman L et al. AS04, an aluminum salt-and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J. Immunol. 183(10), 6186-6197 (2009).
103. Pichyangkul S, Gettayacamin M, Miller RS et al. Pre-clinical evaluation of the malaria vaccine candidate P. falciparum MSP1(42) formulated with novel adjuvants or with alum. Vaccine 22(29-30), 3831-3840 (2004). (Pubitemid 39208744)
104. Brando C, Ware LA, Freyberger H et al. Murine immune responses to liver-stage antigen 1 protein FMP011, a malaria vaccine candidate, delivered with adjuvant AS01B or AS02A. Infect. Immun. 75(2), 838-845 (2007). (Pubitemid 46203447)
105. Agger EM, Rosenkrands I, Hansen J et al. Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements. PloS One 3(9), e3116 (2008).
106. Richards RL, Rao M, Wassef NM, Glenn GM, Rothwell SW, Alving CR. Liposomes containing lipid A serve as an adjuvant for induction of antibody and cytotoxic T-cell responses against RTS,S malaria antigen. Infect. Immun. 66(6), 2859-2865 (1998). (Pubitemid 28261796)
107. + T-cell responses in vivo. Pharm. Res. 28(3), 553-562 (2011).
108. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kB by Toll-like receptor 3. Nature 413(6857), 732-738 (2001). (Pubitemid 33009951)
109. Schulz O, Diebold SS, Chen M et al. Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature 433(7028), 887-892 (2005). (Pubitemid 40314900)
110. + Th1 immunity with poly IC as adjuvant. J. Exp. Med. 206(7), 1589-1602 (2009).
111. Richmond JY, Hamilton LD. Foot-and-mouth disease virus inhibition induced in mice by synthetic double-stranded RNA (polyriboinosinic and polyribocytidylic acids). Proc. Natl Acad. Sci. USA 64(1), 81-86 (1969).
112. Field AK, Tytell AA, Lampson GP, Nemes MM, Hilleman MR. Double-stranded polynucleotides as interferon inducers. J. Gen. Physiol. 56(1), 90-96 (1970).
113. Verdijk RM, Mutis T, Esendam B et al. Polyriboinosinic polyribocytidylic acid (poly(I:C)) induces stable maturation of functionally active human dendritic cells. J. Immunol. 163(1), 57-61 (1999). (Pubitemid 29295824)
114. Sloat BR, Cui Z. Nasal immunization with anthrax protective antigen protein adjuvanted with polyriboinosinic-polyribocytidylic acid induced strong mucosal and systemic immunities. Pharm. Res. 23(6), 1217-1226 (2006). (Pubitemid 43946144)
115. + T cell immunity together with a dendritic cell targeted vaccine. Proc. Natl Acad. Sci. USA 105(7), 2574-2579 (2008). (Pubitemid 351520555)
116. + cytotoxic T lymphocytes. Int. Immunol. 16(1), 55-63 (2004). (Pubitemid 38054627)
117. Salem ML, Kadima AN, Cole DJ, Gillanders WE. Defning the antigen-specifc T-cell response to vaccination and poly(I:C)/TLR3 signaling: evidence of enhanced primary and memory CD8 T-cell responses and antitumor immunity. J. Immunother. 28(3), 220-228 (2005). (Pubitemid 40593987)
118. Freeman AI, Al-Bussam N, O'Malley JA, Stutzman L, Bjornsson S, Carter WA. Pharmacologic effects of polyinosinic-polycytidylic acid in man. J. Med. Virol. 1(2), 79-93 (1977).
119. Cornell Jr. CJ, Smith KA, Cornwell III GG, Burke GP, McIntyre OR. Systemic effects of intravenous polyriboinosinic-polyribocytidylic acid in man. J. Natl Cancer Inst. 57(6), 1211-1216 (1976). (Pubitemid 8009077)
120. + T-cell responses by poly(I:C) incorporated into the CAF01 adjuvant via a double emulsion method. J. Control. Release 150(3), 307-317 (2011).
121. Fujimura T, Nakagawa S, Ohtani T, Ito Y, Aiba S. Inhibitory effect of the polyinosinic-polycytidylic acid/cationic liposome on the progression of murine B16F10 melanoma. Eur. J. Immunol. 36(12), 3371-3380 (2006). (Pubitemid 44932738)
122. Valmori D, Souleimanian NE, Tosello V et al. Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proc. Natl Acad. Sci. USA 104(21), 8947-8952 (2007). (Pubitemid 47175417)
123. + T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide ISA-51: association with survival. Int. J. Cancer 126(4), 909-918 (2010).
124. Kuball J, de Boer K, Wagner E et al. Pitfalls of vaccinations with WT1-, Proteinase3-and MUC1-derived peptides in combination with MontanideISA51 and CpG7909. Cancer Immunol. Immunother. 60(2), 161-171 (2011).
125. Sansonetti PJ. The innate signaling of dangers and the dangers of innate signaling. Nat. Immunol. 7(12), 1237-1242 (2006). (Pubitemid 46111240)
126. Kumar H, Kawai T, Akira S. Pathogen recognition in the innate immune response. Biochem. J. 420, 1-16 (2009).
127. Gitlin L, Barchet W, Gilfllan S et al. Essential role of mda-5 in type I IFN responses to polyriboinosinic:polyribocytidyl ic acid and encephalomyocarditis picornavirus. Proc. Natl Acad. Sci. USA 103(22), 8459-8464 (2006). (Pubitemid 43838477)
128. Kato H, Takeuchi O, Sato S et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 441(7089), 101-105 (2006).
129. Kato H, Takeuchi O, Mikamo-Satoh E et al. Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5. J. Exp. Med. 205(7), 1601-1610 (2008). (Pubitemid 351962024)
130. Eisenbarth SC, Colegio OR, O'Connor W, Sutterwala FS, Flavell RA. Crucial role for the Nalp3 infammasome in the immunostimulatory properties of aluminium adjuvants. Nature 453(7198), 1122-1126 (2008). (Pubitemid 351871731)
131. Kool M, Petrilli V, De ST et al. Cutting edge: alum adjuvant stimulates infammatory dendritic cells through activation of the NALP3 infammasome. J. Immunol. 181(6), 3755-3759 (2008).
132. Franchi L, Nunez G. The Nlrp3 infammasome is critical for aluminium hydroxide-mediated IL-1 b secretion but dispensable for adjuvant activity. Eur. J. Immunol. 38(8), 2085-2089 (2008).
133. Werninghaus K, Babiak A, Gross O et al. Adjuvanticity of a synthetic cord factor analogue for subunit Mycobacterium tuberculosis vaccination requires FcR gamma-Syk-Card9-dependent innate immune activation. J. Exp. Med. 206(1), 89-97 (2009).
134. Schoenen H, Bodendorfer B, Hitchens K et al. Cutting edge: mincle is essential for recognition and adjuvanticity of the mycobacterial cord factor and its synthetic analog trehalose-dibehenate. J. Immunol. 184(6), 2756-2760 (2010).
135. Matzinger P. Tolerance, danger, and the extended family. Annu. Rev. Immunol. 12, 991-1045 (1994). (Pubitemid 24140436)
136. Kono H, Rock KL. How dying cells alert the immune system to danger. Nat. Rev. Immunol. 8(4), 279-289 (2008). (Pubitemid 351432799)
137. Medzhitov R. Origin and physiological roles of infammation. Nature 454(7203), 428-435 (2008).
138. Gallucci S, Lolkema M, Matzinger P. Natural adjuvants: endogenous activators of dendritic cells. Nat. Med. 5(11), 1249-1255 (1999). (Pubitemid 29535601)
139. Matzinger P. Friendly and dangerous signals: is the tissue in control? Nat. Immunol. 8(1), 11-13 (2007). (Pubitemid 46242350)
140. + T cell populations lacking helper function. Nat. Immunol. 6(2), 163-170 (2005). (Pubitemid 40268197)
141. Johansen P, Mohanan D, Martinez-Gomez JM, Kundig TM, Gander B. Lympho-geographical concepts in vaccine delivery. J. Control. Release 148(1), 56-62 (2010).
142. Mohanan D, Slutter B, Henriksen-Lacey M et al. Administration routes affect the quality of immune responses: a cross-sectional evaluation of particulate antigen-delivery systems. J. Control. Release 147(3), 342-349 (2010).
143. Giudice EL, Campbell JD. Needle-free vaccine delivery. Adv. Drug Delivery Rev. 58(1), 68-89 (2006).
144. Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat. Med. 11(4), S45-S53 (2005). (Pubitemid 40562303)
145. Cerutti A, Chen K, Chorny A. Immunoglobulin responses at the mucosal interface. Annu. Rev. Immunol. 29, 273-293 (2011).
146. Mestecky J. The common mucosal immune system and current strategies for induction of immune responses in external secretions. J. Clin. Immunol. 7(4), 265-276 (1987). (Pubitemid 17146794)
147. Gill N, Wlodarska M, Finlay BB. The future of mucosal immunology: studying an integrated system-wide organ. Nat. Immunol. 11(7), 558-560 (2010).
148. Gallichan WS, Woolstencroft RN, Guarasci T, McCluskie MJ, Davis HL, Rosenthal KL. Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract. J. Immunol. 166(5), 3451-3457 (2001). (Pubitemid 33117348)
149. Chen K, Cerutti A. Vaccination strategies to promote mucosal antibody responses. Immunity 33(4), 479-491 (2010).
150. Freytag LC, Clements JD. Mucosal adjuvants. Vaccine 23(15), 1804-1813 (2005). (Pubitemid 40331849)
151. Chadwick S, Kriegel C, Amiji M. Nanotechnology solutions for mucosal immunization. Adv. Drug Delivery Rev. 62(4-5), 394-407 (2010).
152. Slutter B, Hagenaars N, Jiskoot W. Rational design of nasal vaccines. J. Drug Targeting 16(1), 1-17 (2008).
153. Jabbal-Gill I. Nasal vaccine innovation. J. Drug Targeting 18(10), 771-786 (2010).
154. Baudner BC, O'Hagan DT. Bioadhesive delivery systems for mucosal vaccine delivery. J. Drug Targeting 18(10), 752-770 (2010).
155. Lu D, Hickey AJ. Pulmonary vaccine delivery. Expert Rev. Vaccines 6(2), 213-226 (2007). (Pubitemid 46607457)
156. Blank F, Stumbles P, von Garnier C. Opportunities and challenges of the pulmonary route for vaccination. Expert Opin. Drug Deliv. 8(5), 547-563 (2011).
157. Omer SB, Hiremath GS, Halsey NA. Respiratory administration of measles vaccine. Lancet 375(9716), 706-708 (2010).
158. Patton JS, Byron PR. Inhaling medicines: delivering drugs to the body through the lungs. Nat. Rev. Drug Discovery 6(1), 67-74 (2007). (Pubitemid 46020287)
159. Ingvarsson PT, Yang M, Nielsen HM, Rantanen J, Foged C. Stabilization of liposomes during drying. Expert Opin. Drug Deliv. 8(3), 375-388 (2011).
160. Sou T, Meeusen EN, de VM, Morton DA, Kaminskas LM, McIntosh MP. New developments in dry powder pulmonary vaccine delivery. Trends Biotechnol. 29(4), 191-198 (2011).
161. Azizi A, Kumar A, az-Mitoma F, Mestecky J. Enhancing oral vaccine potency by targeting intestinal M cells. PLoS Pathog. 6(11), e1001147 (2010).
162. Mann JFS, Acevedo R, del Campo J, Perez O, Ferro VA. Delivery systems: a vaccine strategy for overcoming mucosal tolerance? Expert Rev. Vaccines 8(1), 103-112 (2008).
163. Devriendt B, De Geest BG, Cox E. Designing oral vaccines targeting intestinal dendritic cells. Expert Opin. Drug Deliv. 8(4), 467-483 (2011).
164. Bal SM, Ding Z, van RE, Jiskoot W, Bouwstra JA. Advances in transcutaneous vaccine delivery: do all ways lead to Rome? J. Control. Release 148(3), 266-282 (2010).
165. Bal SM, Kruithof AC, Zwier R et al. Infuence of microneedle shape on the transport of a fuorescent dye into human skin in vivo. J. Control. Release 147(2), 218-224 (2010).
166. Bal SM, Ding Z, Kersten GF, Jiskoot W, Bouwstra JA. Microneedle-based transcutaneous immunisation in mice with N-trimethyl chitosan adjuvanted diphtheria toxoid formulations. Pharm. Res. 27(9), 1837-1847 (2010).
167. Bal SM, Slutter B, Jiskoot W, Bouwstra JA. Small is beautiful: N-trimethyl chitosan-ovalbumin conjugates for microneedle-based transcutaneous immunisation. Vaccine 29(23), 4025-4032 (2011).
168. Bal SM, Slutter B, van Riet E et al. Effcient induction of immune responses through intradermal vaccination with N-trimethyl chitosan containing antigen formulations. J. Control. Release 142(3), 374-383 (2010).
169. Morefeld GL. A rational, systematic approach for the development of vaccine formulations. AAPS J. 13(2), 191-200 (2011).
170. Xiang SD, Scholzen A, Minigo G et al. Pathogen recognition and development of particulate vaccines: Does size matter? Methods 40(1), 1-9 (2006). (Pubitemid 44415493)
171. Foged C, Brodin B, Frokjaer S, Sundblad A. Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model. Int. J. Pharm. 298(2), 315-322 (2005). (Pubitemid 40910735)
172. Kersten GF, Crommelin DJ. Liposomes and ISCOMs. Vaccine 21(9-10), 915-920 (2003). (Pubitemid 36126426)
173. Oyewumi MO, Kumar A, Cui Z. Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses. Expert Rev. Vaccines 9(9), 1095-1107 (2010).
174. Bachmann MF, Jennings GT. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat. Rev. Immunol. 10(11), 787-796 (2010).
175. Kovacsovics-Bankowski M, Clark K, Benacerraf B, Rock KL. Effcient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages. Proc. Natl Acad. Sci. USA 90(11), 4942-4946 (1993) (Pubitemid 23182951)
176. Reis e Sousa C, Stahl PD, Austyn JM. Phagocytosis of antigens by Langerhans cells in vitro. J. Exp. Med. 178(2), 509-519 (1993). (Pubitemid 23218199)
177. Watts C. Antigen processing in the endocytic compartment. Curr. Opin. Immunol. 13(1), 26-31 (2001). (Pubitemid 32096956)
178. + T cell vaccines: it's not rocket science (yet). Curr. Opin. Immunol. 22(3), 402-410 (2010).
179. Reis e Sousa C, Germain RN. Major histocompatibility complex class I presentation of peptides derived from soluble exogenous antigen by a subset of cells engaged in phagocytosis. J. Exp. Med. 182(3), 841-851 (1995).
180. Kovacsovics-Bankowski M, Rock KL. A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules. Science 267(5195), 243-246 (1995).
181. Oussoren C, Storm G. Liposomes to target the lymphatics by subcutaneous administration. Adv. Drug Delivery Rev. 50(1-2), 143-156 (2001). (Pubitemid 32727280)
182. Swartz MA. The physiology of the lymphatic system. Adv. Drug Delivery Rev. 50(1-2), 3-20 (2001).
183. Manolova V, Flace A, Bauer M, Schwarz K, Saudan P, Bachmann MF. Nanoparticles target distinct dendritic cell populations according to their size. Eur. J. Immunol. 38(5), 1404-1413 (2008).
184. Vos Q, Lees A, Wu ZQ, Snapper CM, Mond JJ. B-cell activation by T-cell-independent type 2 antigens as an integral part of the humoral immune response to pathogenic microorganisms. Immunol. Rev. 176, 154-170 (2000).
185. Rosenberg AS. Effects of protein aggregates: an immunologic perspective. AAPS J. 8(3), E501-E507 (2006). (Pubitemid 44294011)
186. Steinman RM, Bonifaz L, Fujii S et al. The innate functions of dendritic cells in peripheral lymphoid tissues. Adv. Exp. Med. Biol. 560, 83-97 (2005).
187. den Haan JM, Lehar SM, Bevan MJ. CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo. J. Exp. Med. 192(12), 1685-1696 (2000).
188. Cella M, Jarrossay D, Facchetti F et al. Plasmacytoid monocytes migrate to infamed lymph nodes and produce large amounts of type I interferon. Nat. Med. 5(8), 919-923 (1999). (Pubitemid 29372419)
189. Villadangos JA, Schnorrer P. Intrinsic and cooperative antigen-presenting functions of dendritic-cell subsets in vivo. Nat. Rev. Immunol. 7(7), 543-555 (2007). (Pubitemid 46987783)
190. Fifs T, Gamvrellis A, Crimeen-Irwin B et al. Size-dependent immunogenicity: Therapeutic and protective properties of nano-vaccines against tumors. J. Immunol. 173(5), 3148-3154 (2004). (Pubitemid 39142021)
191. Korsholm KS, Agger EM, Foged C et al. The adjuvant mechanism of cationic dimethyldioctadecylammonium liposomes. Immunology 121(2), 216-226 (2007). (Pubitemid 46663090)
192. Foged C, Arigita C, Sundblad A, Jiskoot W, Storm G, Frokjaer S. Interaction of dendritic cells with antigen-containing liposomes: effect of bilayer composition. Vaccine 22(15-16), 1903-1913 (2004). (Pubitemid 38581059)
193. Thiele L, Rothen-Rutishauser B, Jilek S, Wunderli-Allenspach H, Merkle HP, Walter E. Evaluation of particle uptake in human blood monocyte-derived cells in vitro. Does phagocytosis activity of dendritic cells measure up with macrophages? J. Control. Release 76(1-2), 59-71 (2001). (Pubitemid 32786885)
194. Walter E, Dreher D, Kok M et al. Hydrophilic poly(DL-lactide-co- glycolide) microspheres for the delivery of DNA to human-derived macrophages and dendritic cells. J. Control. Release 76(1-2), 149-168 (2001). (Pubitemid 32786893)
195. Kidane A, Guimond P, Rob Ju Tc et al. Effects of cellulose derivatives and poly(ethylene oxide)-poly(propylene oxide) tri-block copolymers (Pluronic surfactants) on the properties of alginate based microspheres and their interactions with phagocytic cells. J. Control. Release 85(1-3), 181-189 (2002). (Pubitemid 35449464)
196. Thomas CM, Rawat A, Hope-Weeks LJ, Ahsan F. Aerosolized PLA and PLGA nanoparticles enhance humoral, mucosal and cytokine responses to hepatitis B vaccine. Mol. Pharm. (2010).
197. Singh J, Pandit S, Bramwell VW, Alpar HO. Diphtheria toxoid loaded poly-([e]-caprolactone) nanoparticles as mucosal vaccine delivery systems. Methods 38(2), 96-105 (2006). (Pubitemid 43163469)
198. Seong SY, Matzinger P. Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses. Nat. Rev. Immunol. 4(6), 469-478 (2004). (Pubitemid 38745558)
199. Champion JA, Mitragotri S. Role of target geometry in phagocytosis. Proc. Natl Acad. Sci. USA 103(13), 4930-4934 (2006).
200. World Health Organization. Manual for production and control of vaccines-tetanous toxoid. Geneva: World Health Organization (1977)
201. Hansen B, Sokolovska A, Hogenesch H, Hem SL. Relationship between the strength of antigen adsorption to an aluminum-containing adjuvant and the immune response. Vaccine 25(36), 6618-6624 (2007). (Pubitemid 47211514)
202. Romero MI, Shi Y, Hogenesch H, Hem SL. Potentiation of the immune response to non-adsorbed antigens by aluminum-containing adjuvants. Vaccine 25(5), 825-833 (2007). (Pubitemid 44856127)
203. Jorgensen L, Wood GK, Rosenkrands I, Petersen C, Christensen D. Protein adsorption and displacement at lipid layers determined by total internal refection fuorescence (TIRF). J. Liposome Res. 19(2), 99-104 (2009).
204. Jones LS, Peek LJ, Power J, Markham A, Yazzie B, Middaugh CR. Effects of adsorption to aluminum salt adjuvants on the structure and stability of model protein antigens. J. Biol. Chem. 280(14), 13406-13414 (2005). (Pubitemid 40517228)
205. Jemmerson R, Margoliash E. Topographic antigenic determinants on cytochrome c. Immunoadsorbent separation of the rabbit antibody populations directed against horse cytochrome c. J. Biol. Chem. 254(24), 12706-12716 (1979). (Pubitemid 10137662)
206. Thai R, Moine G, Desmadril M et al. Antigen stability controls antigen presentation. J. Biol. Chem. 279(48), 50257-50266 (2004). (Pubitemid 39577840)
207. Podda A. The adjuvanted infuenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine 19(17-19), 2673-2680 (2001). (Pubitemid 32234288)
208. Pearse MJ, Drane D. Iscomatrix adjuvant for antigen delivery. Adv. Drug Delivery Rev. 57(3), 465-474 (2005).